2020 TSOC共识:2型糖尿病合并心血管疾病患者药物治疗

2020-07-05 台湾心脏病学会 J Chin Med Assoc . 2020 Jul;83(7):587-621.

2020年7月,台湾心脏病学会(TSOC)发布了2型糖尿病合并心血管疾病患者药物治疗共识,近几十年,全球范围内糖尿病的发病率和患病率不断攀升,2型糖尿病患者发生动脉硬化性心血管疾病(ASCVD)的风险

中文标题:

2020 TSOC共识:2型糖尿病合并心血管疾病患者药物治疗

英文标题:

2020 Consensus of Taiwan Society of Cardiology on the Pharmacological Management of Patients With Type 2 Diabetes and Cardiovascular Diseases

发布机构:

台湾心脏病学会

发布日期:

2020-07-05

简要介绍:

2020年7月,台湾心脏病学会(TSOC)发布了2型糖尿病合并心血管疾病患者药物治疗共识,近几十年,全球范围内糖尿病的发病率和患病率不断攀升,2型糖尿病患者发生动脉硬化性心血管疾病(ASCVD)的风险增加,约有2/3的糖尿病患者死于ASCVD。本文合租要针对2型糖尿病合并心血管疾病患者药物治疗提供共识建议,主要涉及5个部分,分别为:1.多危险因素糖尿病的治疗;2.糖尿病合并冠心病的治疗;3.糖尿病合并3期肾脏病的治疗;4.既往卒中史的糖尿病患者的治疗;5.心衰患者糖尿病的治疗。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2020 TSOC共识:2型糖尿病合并心血管疾病患者药物治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=d68a01c001939831, title=2020 TSOC共识:2型糖尿病合并心血管疾病患者药物治疗, enTitle=2020 Consensus of Taiwan Society of Cardiology on the Pharmacological Management of Patients With Type 2 Diabetes and Cardiovascular Diseases, guiderFrom=J Chin Med Assoc . 2020 Jul;83(7):587-621., authorId=0, author=, summary=2020年7月,台湾心脏病学会(TSOC)发布了2型糖尿病合并心血管疾病患者药物治疗共识,近几十年,全球范围内糖尿病的发病率和患病率不断攀升,2型糖尿病患者发生动脉硬化性心血管疾病(ASCVD)的风险, cover=https://img.medsci.cn/2020726/1595778071064_2020535.jpg, journalId=0, articlesId=null, associationId=267, associationName=台湾心脏病学会, associationIntro=null, copyright=0, guiderPublishedTime=Sun Jul 05 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年7月,台湾心脏病学会(TSOC)发布了2型糖尿病合并心血管疾病患者药物治疗共识,近几十年,全球范围内糖尿病的发病率和患病率不断攀升,2型糖尿病患者发生动脉硬化性心血管疾病(ASCVD)的风险增加,约有2/3的糖尿病患者死于ASCVD。本文合租要针对2型糖尿病合并心血管疾病患者药物治疗提供共识建议,主要涉及5个部分,分别为:1.多危险因素糖尿病的治疗;2.糖尿病合并冠心病的治疗;3.糖尿病合并3期肾脏病的治疗;4.既往卒中史的糖尿病患者的治疗;5.心衰患者糖尿病的治疗。</p> </div> </div> </div>, tagList=[TagDto(tagId=2052, tagName=2型糖尿病)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=43, categoryName=冠心病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=2052, guiderKeyword=2型糖尿病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5013, appHits=417, showAppHits=0, pcHits=663, showPcHits=4596, likes=5, shares=26, comments=25, approvalStatus=1, publishedTime=Mon Jul 27 00:11:20 CST 2020, publishedTimeString=2020-07-05, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sun Jul 26 23:41:19 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 15:19:43 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 TSOC共识:2型糖尿病合并心血管疾病患者药物治疗.pdf)])
2020 TSOC共识:2型糖尿病合并心血管疾病患者药物治疗.pdf
下载请点击:
评论区 (18)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1198009, encodeId=f11611980096d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=136b6526103, createdName=ms7000001920761085, createdTime=Mon Feb 28 14:10:19 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952575, encodeId=0a9a9525e53b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhh6qsBGWPf2DhGRYSIcYMzghKu6o9XJumGnias3YIYXdlRfS6h1Z54iccWe7za6y3a5K6YWGYlzPw/132, createdBy=b6f05346814, createdName=ms2192709503874843, createdTime=Wed Mar 31 08:49:12 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899407, encodeId=338889940e7c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4e55204402, createdName=147471c7m80暂无昵称, createdTime=Sun Nov 15 23:23:06 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895819, encodeId=4c3189581911, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=588c5430556, createdName=ms4000001185481331, createdTime=Sat Oct 31 09:48:33 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884504, encodeId=5270884504db, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c495209553, createdName=1475877fm90暂无昵称, createdTime=Fri Sep 11 10:45:54 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
    2022-02-28 ms7000001920761085

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1198009, encodeId=f11611980096d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=136b6526103, createdName=ms7000001920761085, createdTime=Mon Feb 28 14:10:19 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952575, encodeId=0a9a9525e53b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhh6qsBGWPf2DhGRYSIcYMzghKu6o9XJumGnias3YIYXdlRfS6h1Z54iccWe7za6y3a5K6YWGYlzPw/132, createdBy=b6f05346814, createdName=ms2192709503874843, createdTime=Wed Mar 31 08:49:12 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899407, encodeId=338889940e7c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4e55204402, createdName=147471c7m80暂无昵称, createdTime=Sun Nov 15 23:23:06 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895819, encodeId=4c3189581911, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=588c5430556, createdName=ms4000001185481331, createdTime=Sat Oct 31 09:48:33 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884504, encodeId=5270884504db, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c495209553, createdName=1475877fm90暂无昵称, createdTime=Fri Sep 11 10:45:54 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
    2021-03-31 ms2192709503874843

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1198009, encodeId=f11611980096d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=136b6526103, createdName=ms7000001920761085, createdTime=Mon Feb 28 14:10:19 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952575, encodeId=0a9a9525e53b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhh6qsBGWPf2DhGRYSIcYMzghKu6o9XJumGnias3YIYXdlRfS6h1Z54iccWe7za6y3a5K6YWGYlzPw/132, createdBy=b6f05346814, createdName=ms2192709503874843, createdTime=Wed Mar 31 08:49:12 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899407, encodeId=338889940e7c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4e55204402, createdName=147471c7m80暂无昵称, createdTime=Sun Nov 15 23:23:06 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895819, encodeId=4c3189581911, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=588c5430556, createdName=ms4000001185481331, createdTime=Sat Oct 31 09:48:33 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884504, encodeId=5270884504db, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c495209553, createdName=1475877fm90暂无昵称, createdTime=Fri Sep 11 10:45:54 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
    2020-11-15 147471c7m80暂无昵称

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1198009, encodeId=f11611980096d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=136b6526103, createdName=ms7000001920761085, createdTime=Mon Feb 28 14:10:19 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952575, encodeId=0a9a9525e53b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhh6qsBGWPf2DhGRYSIcYMzghKu6o9XJumGnias3YIYXdlRfS6h1Z54iccWe7za6y3a5K6YWGYlzPw/132, createdBy=b6f05346814, createdName=ms2192709503874843, createdTime=Wed Mar 31 08:49:12 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899407, encodeId=338889940e7c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4e55204402, createdName=147471c7m80暂无昵称, createdTime=Sun Nov 15 23:23:06 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895819, encodeId=4c3189581911, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=588c5430556, createdName=ms4000001185481331, createdTime=Sat Oct 31 09:48:33 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884504, encodeId=5270884504db, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c495209553, createdName=1475877fm90暂无昵称, createdTime=Fri Sep 11 10:45:54 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
    2020-10-31 ms4000001185481331

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1198009, encodeId=f11611980096d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=136b6526103, createdName=ms7000001920761085, createdTime=Mon Feb 28 14:10:19 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952575, encodeId=0a9a9525e53b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhh6qsBGWPf2DhGRYSIcYMzghKu6o9XJumGnias3YIYXdlRfS6h1Z54iccWe7za6y3a5K6YWGYlzPw/132, createdBy=b6f05346814, createdName=ms2192709503874843, createdTime=Wed Mar 31 08:49:12 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899407, encodeId=338889940e7c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4e55204402, createdName=147471c7m80暂无昵称, createdTime=Sun Nov 15 23:23:06 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895819, encodeId=4c3189581911, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=588c5430556, createdName=ms4000001185481331, createdTime=Sat Oct 31 09:48:33 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884504, encodeId=5270884504db, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c495209553, createdName=1475877fm90暂无昵称, createdTime=Fri Sep 11 10:45:54 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
    2020-09-11 1475877fm90暂无昵称

    学习

    0

拓展阅读

2014 ADS立场声明:2型糖尿病血糖管理法则

澳大利亚糖尿病协会(ADS,Australian Diabetes Society) · 2014-12-11

2015 AHA/ADA科学声明:成人2型糖尿病患者心血管疾病的预防(更新版)

美国糖尿病学会(ADA,American Diabetes Association) · 2015-08-05

2015 ADA/AADE/AND联合声明:2型糖尿病的自我管理教育和支持

美国糖尿病学会(ADA,American Diabetes Association) · 2015-06-05

2013 中国2型糖尿病防治指南(2013年版)

中华医学会糖尿病学分会(CDS,Chinese Diabetes Society) · 2014-08-16